Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research note issued to investors on Monday.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI stock opened at $1.89 on Monday. Brainstorm Cell Therapeutics has a 12 month low of $1.05 and a 12 month high of $11.89. The company has a market capitalization of $10.77 million, a PE ratio of -0.39 and a beta of 0.29. The firm’s 50-day moving average is $1.81 and its two-hundred day moving average is $3.12.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.